Multi-omic profiling (DNA methylation, RNA-seq, H3K27ac and H3K27me3) of 98 metastatic CRPC samples from 35 patients reveals patient-specific epigenetic signatures and methylation-driven regulation of lineage genes and therapeutic targets. Integrative analyses identify >21,000 region–gene links and highlight intraindividual heterogeneity including double-negative tumors with BMP4 signaling or immune-high profiles.
0:00Welcome to Base by Base, the paper cast that brings genomics to you wherever you are. Thanks for listening, and don't forget to follow and rate us in your podcast app. What really happens when a tumor decides to change its identity completely just to survive.
0:12Well, you know, we usually think of cancer as like a static target. You find it. Map its vulnerabilities and expect it to shrink. Right. Hit it with a drug and it's gone. Okay. But in the real world of oncology, therapy resistance is huge.
0:28Tumors adapt. And not just a little bit. Some tumors, they completely rewrite their internal blueprints. Yeah, turning into a totally different cell type entirely to evade treatment. It's, well, it's a shapeshifting act at a microscopic level.
0:42How could mapping this invisible blueprint change the way we track and corner advanced cancers before they make their next move? It's a pretty profound biological problem. And today we celebrate the work of Kai Mizuno, Himisha Beltran, and their extensive team of researchers.
0:57Right. And institutions, including the Dana Farber Cancer Institute, and while Cornell Medicine, who have advanced our understanding of how tumors rewire themselves. Yeah, this deep dive is based on their article titled entry individual, epigenetic, heterogeneity, underlying phenotypic subtypes of advanced prostate cancer, published in the journal Nature Communications on July 1st, 2025.
1:20So let's jump into the clinical problem. We're looking at cast creation resistant prostate cancer or CRPC. Exactly. Prostate cancer typically starts out as an ad no carcinoma, which is driven by the androgen receptor, the AR.
1:34And standard treatment blocks that receptor, right? Like cutting off the fuel supply. Right. But in, I mean, 15 to 20% of cases, the cancer develops resistance. changes lineage. Like turning into neuroendocrine prostate cancer or NEPC, which loses AR dependence entirely.
1:50Okay, let's unpack this. It's like a criminal changing their disguise. The police are looking for the androgen receptor jacket. So the tumor takes it off and puts on a neuroendocrine hat instead. That's great analogy.
2:01And the problem clinically is that doctors usually diagnose this shift using just a single biopsy. But if the cancer has spread, you know, metastasized, does every tumor wear the same disguise or do they vary?
2:12That is exactly the critical gap this study fills. If it changes in the liver, Does it change in the bone? So to catch a shapeshifter across multiple locations, You can't just look at one crime scene. You have to look at all of them at once.
2:24Right. So they looked at 98 tumor samples from 35 patients with metastatic CRPC. And crucially, 21 of these were rapid autopsy cases. Yeah, which is incredible, allowing the team to sample multiple anatomical sites from the exact same patient.
2:38Like the liver bone, lymph nodes, and to see the whole patient, they use multi-omix. Exactly. They used RNA sequencing for reading the active genes and RRBS to measure DNA methylation. The chemical padlocks, essentially.
2:52Right. And Chippy Sec and CTM Tag to look at histone modifications, like H3K 27 AC and H3K 27 E3. Okay, wait, let's slow down. So what does this all mean for the DNA? How is a histone different from methylation?
3:04Well, think of methylation as placing a physical block or a padlock directly on the DNA sequence. Oh, got it. So it locks the gene down and the histones. His stones are the spools the DNA is wrapped around.
3:16If you tighten the spool, that's the H3K 27 M3 mark. The gene is hidden. But if you loosen this bowl with H3K 27 AC, it's active. You got it. So now we have the map of these padlocks and spools. Right.
3:31What did the map actually reveal? The 1st major finding was a really surprising amount of stability. Global DNA methylation patterns were highly conserved across different metastases within the same patient.
3:43Wait, really? So the patient's unique biological signature influenced the pattern more than where the tumor was physically located. Exactly. A lung metastasis looked more like a bone metastasis from the same patient than it did to someone else's lung metastasis.
3:56But there's a butt here, right? Yes. Despite that global stability, finding 2 showed intra individual heterogeneity. Five patients had entirely different tumor subtypes across their body. Oh, wow. So like an AR positive tumor in the liver, put a double negative tumor in a lymph node?
4:12Precisely. And finding 3 pinpointed the epigenetic switches making that happen. They found over 20,000 regions where DNA methylation directly controlled gene expression. Like the Gene A is CL1, the neuroendocrine driver, right?
4:24Right. It turns on when it loses methylation and gains those active, loose bull histone marks. Therapeutic targets, uh, like P SMA, which is FOLH1 and DLO3, are also regulated by these exact same padlocks.
4:37Yeah, the tumor uses epigenetics to hide the very proteins our drugs target. That brings us to finding four, the double negative split. Right. For tumors that lose AR, but don't become neuroendocrine. What's driving them?
4:49They found 2 distinct molecular pathways here. First, a high BMP 4 signaling pathway. And the second. An immune high pathway, driven by genes like VAV1 and IL4R, showing, you know, high immune cell infiltration.
5:03Here's where it gets really interesting. In the lab, they took DU 145 double negative cancer cells. Yeah, and they treated them with LDN 193, 189. Right, an inhibitor targeting that BMP 4 pathway. And they saw a massive 68% decrease in cell viability.
5:20It's huge drop. The unspooled BMP 4 pathway is clearly a critical vulnerability for that subtype. So what does all this mean for the future of oncology? We're looking at liquid biopsies, right? Exactly.
5:31Because those global epigenetic changes are relatively stable, doctors might soon monitor a patient's blood using cell-free DNA or CF DNA. To see if a tumor's rewiring its targets like PSMA or B7H3. In real time.
5:45Right, which dictates exactly when to switch to specific targeted therapies. And for those double negative variants. Well, high BMP 4 tumors might respond to targeted inhibitors, while immune high tumors might be candidates for immunotherapy.
5:59But you know, we always have to look at the limitations. The BMP 4 survival data didn't quite reach statistical significance, right? Yeah, unfortunately due to a very small sample size. And future studies need to look at other histone marks, too.
6:13Like H3K4ME1 to get the complete picture. Right. the whole regulatory landscape. Got it. So just to summarize everything, advanced prostate cancer evades treatment, not just by mutating, but by using epigenetic padlocks and spools, to entirely rewrite its cellular identity.
6:29Exactly. And by mapping these changes, researchers have proven that distinct targetable tumor subtypes can coexist within the exact same patient. Opening the door to highly personalized dynamic treatment strategies.
6:41What does this mean for the future of personalized medicine, where treating cancer means tracking its evolving epigenetic disguises in real time? It's a shift that could change everything about how we corner this disease.
6:53This episode was based on an open access article under the CCBY 4.0 license. You can find a direct link to the paper and the license in our episode description. If you enjoyed this, follow or subscribe in your podcast app and leave a five-star rating.
7:08If you'd like to support our work, use the donation link in the description. Now, stay with us for an original track, created especially for this episode, and inspired by the article you've just heard about.
7:16Thanks for listening, and join us next time as we explore more science based by base.
